Kenneth Lim

[Saurabh Zanwar @ZanwarSaurabh]

Out now in @AjHematology! We identify factors associated with early treatment failure (PFS <12 months) in patients with R/R myeloma receiving cilta-cel and identify early prognostic markers

Key takeaways:
✅ Early failure noted in Prior BCMA-directed Rx, EMD and higher ferritin/cytopenias at baseline
⭐️ No difference in PFS or early failure for early (1-3) vs later(≥4) lines of therapy
⭐️ BM MRD or PET positivity at 3 months post infusion markedly prognostic. Need consideration for consolidation in these patients?

🧵 1/

https://t.co/szBjyW42pc

[VJHemOnc @VJHemOnc]

Don't miss our newest podcast episode, which focuses on adverse events in the post #CARTCell therapy setting and covers:

🩸Infection incidence and prevention
🩸Less common toxicities
🩸& more!

Check it out here:
🎧 ➡️ https://t.co/lsNKSGbiTJ

Featuring @MSubklewe, @ErikaKampouri, Birte Friedrichs, @heMEGirl_MD, & @Kennethjclim

#ImmunoOnc #DLBCL #LYMsm #Lymphoma #MMSM #Myeloma #MultipleMyeloma #HemOnc

[Hamza Hashmi @hhashmi87]

This paper is a great read and addresses an area of uncertainty in #Myeloma

Should we consider treating SBPmm with HR CG (del17p, 1q) like Myeloma? @Rfonsi1 @RahulBanerjeeMD @VincentRK @brandon_imber

A multi-center study of progression-risk and outcomes in solitary bone plasmacytoma with and without marrow involvement https://t.co/mmUVex5KW7

[VJHemOnc @VJHemOnc]

This week's podcast episode is live!🎧

Hear as leading experts discuss adverse events in the post #CARTCell therapy setting, from infections to less common toxicities, and provide valuable advice on their prevention and management.🩸

Listen now: 👉 https://t.co/lsNKSGbiTJ

Featuring @MSubklewe, @ErikaKampouri, Birte Friedrichs, @heMEGirl_MD, & @Kennethjclim

#ImmunoOnc #DLBCL #LYMsm #Lymphoma #MMSM #Myeloma #MultipleMyeloma #HemOnc

[Yi Lin @YiLinMDPhD]

High ALC after Cilta-cel is associated with increased risk of IEC-Parkinsonism. Can DEX decrease ALC &amp; reduce risk for this toxicity? Dr. Ken Lim presents @MayoCancerCare expeirence today #Tandem2026 #mmsm #CART. 🧠💊@ASTCT @VincentRK @RahulBanerjeeMD
https://t.co/KtMaNXwTtO

[Joselle Cook @JoselleCookMD]

📍ASH guidelines on diagnosis of AL amyloidosis 2026. ➡️Two years of meetings and collaboration with an interdisciplinary international team.

[Yi Lin @YiLinMDPhD]

Great job @Kennethjclim presenting @MayoCancerCare risk factor of IEC-nerve palsy &amp; Parkinsonism #EHA25 #mmsm Hopefully we will learn soon from CARTITUDE trials &amp; RWE across centers whether additional early mitigating strategies could reduce the risk further @IMFmyeloma

[Yi Lin @YiLinMDPhD]

Poster session now #EHA25 @Kennethjclim presents real world analysis of risk factors for IEC-enterocolitis (PS2152) &amp; non-ICANS Neurotox (oral presentation Sunday Brown Hall 11AM). With impressive PFS seen from cilta-cel, important to work on reducing tox @MayoCancerCare

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

2/ Independent proof of this principle from another of my top 10 #Tandem25 posters, this time by @YiLinMDPhD @Rfonsi1 @MayoMyeloma et al:

If peak ALC &gt;3.0 after #MMsm CAR-T, 29% MNT risk if 3% if not.

If Parkinsonism happens, use high-dose Cy quickly - possible Sx resolution.

[Rahul Banerjee, MD, FACP @RahulBanerjeeMD]

1/ The "this shoulda been an oral" #MMsm poster of #Tandem25 - worth reviewing if you use cilta-cel!

Rapid or sustained ALC ⬆️⬆️ appear to drive tox with BCMA CAR-T.

CBCI now starting dex preemptively if ALC > 5.0 even if no tox yet - well-powered RCT hopefully coming soon!

[Multiple Myeloma Hub @MM_Hub]

CONGRESS | POSTER | #ASH23 | Kenneth J C Lim @StVincentsMelb presents on the impact of 1Q21+ in daratumumab treated MM. median PFS with vs without 1q21+ 9.2-mo vs 22.1-mo. Median PFS gain1q21 vs amp1q21 5.7-mo vs 10.5mo.
#mmsm #myeloma